Marker Therapeutics (NASDAQ:MRKR) Shares Down 8.5% – Here’s Why

Marker Therapeutics, Inc. (NASDAQ:MRKR)’s stock price dropped 8.5% during trading on Monday . The stock traded as low as $3.52 and last traded at $3.79. Approximately 26,219 shares were traded during mid-day trading, an increase of 2% from the average daily volume of 25,676 shares. The stock had previously closed at $4.14.

Analysts Set New Price Targets

Separately, LADENBURG THALM/SH SH increased their price objective on Marker Therapeutics from $11.00 to $19.00 and gave the stock a “buy” rating in a research report on Monday, October 21st.

Marker Therapeutics Stock Down 2.2 %

The business has a 50 day moving average price of $3.27 and a two-hundred day moving average price of $3.93.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.25) earnings per share (EPS) for the quarter. Marker Therapeutics had a negative return on equity of 78.91% and a negative net margin of 278.27%. The business had revenue of $1.17 million for the quarter. On average, analysts expect that Marker Therapeutics, Inc. will post -1.43 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

An institutional investor recently raised its position in Marker Therapeutics stock. Wedbush Securities Inc. increased its position in Marker Therapeutics, Inc. (NASDAQ:MRKR) by 52.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 69,500 shares of the company’s stock after purchasing an additional 24,000 shares during the quarter. Wedbush Securities Inc. owned approximately 0.78% of Marker Therapeutics worth $377,000 at the end of the most recent quarter. 22.39% of the stock is owned by institutional investors.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.